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Several investigations have demonstrated that Rosa damascena has an
inhibitory effect on the hypothalamus and on pituitary system reactivity
in the rat; it has also been shown that the essential oil of Rosa damascena
has significant antiepileptic effects on pentylentetrazole (PTZ) induced
seizures in rats. We aimed at assessing the effects of the essential oil of
Rosa damascena when used as an adjunct treatment to treat children with
refractory seizures
Materials and Methods
In this double-blind clinical trial, conducted as a pilot study between April
2004 and March 2005, we administered essential oil of Rosa damascena
to sixteen children with refractory epilepsy as an adjunct therapy, and
evaluated its effects.
Results
16 patients, age range 3-13 years, were enrolled; 56.3% (n=9) girls and
43.8% (n=7) boys.
All has been under treatment for 3-6 weeks (baseline phase). They received
either the essential oil or placebo for a period of 4 weeks and in between
these periods, they took only their pre-existing antiepileptic drugs for two
weeks (washout phase).
The mean frequency of seizures in those using essential oil, showed
significant decrease as compared to the controls using placeboes (p=0.00).
Conclusion
It can be concluded that the essential oil of Rosa Damascena has beneficial
antiepileptic effect in children with refractory seizures.
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Introduction
Rosa damascena, an erect shrub 1-2 meter in height, has large, colorful flowers. Today
Rosa damascena is highly cultivated for its scent (1-2). This plant contains carboxylic
acids, terpenes, myrcene and vitamin c (1, 3, 4). The flowers, petals and hips (seed-
pots) of Rosa damascena have been used for medical purposes. Rosa damascena has
been used for various conditions including menstrual bleeding, digestive disorders
and headache (1-2-3). Its anti HIV and antibacterial effect has also been reported (4-
5-6). Certain herbal eye drops (Opthafare) also contain Rosa (7).
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Materials and Methods
This double blind, placebo controlled study was performed
in a tertiary referral center between "April 2004 to March
2005". Sixteen patients were enrolled, following signing
of informed consent (table 1). Patients were eligible for
enrollment if they were 3-13 years old, and had
unequivocal seizures that were refractory to current anti-
epileptic drugs (AEDs), and had to have intractable
epilepsy according to accepted definition (11). Those
who had progressive diseases or cardiac, lung, liver or
renal diseases were excluded.
In spring 2004, Rosa damascena was collected from
Kalat, in the north-east of Iran; a voucher specimen was
preserved in the herbarium of the school of pharmacy,
Mashhad university of medical sciences (herbarium No:
254-1804-ol). To prepare the oil for each use, 500 gram
of the chopped and dried plant with 5000 ml distilled
water, was needed to extract 5 ml oil, using the steam
distilled apparatus; the plant ingredient concentration in
the essential oil was 10 gr% V/V (8-9-10). A 10%
concentration of oil with medium chain triglyceride was
prepared and the dose prescribed was 5 mg/kg/dose three
times per day (1/20 of experimental dose) (8-9-10);
placebo was also administered similarly.
When enrolled for the 3-6 weeks (baseline phase) patients
received their customary AEDs, and were observed for
the types, frequency and duration of their seizures; they
were then initially given either oil or placebo as add-on
therapy with 5mg/kg/dose three times per day for four
weeks (treatment phase) and after a washout period (2
weeks) they received the other, placebo or oil, while they
were blinded to the content. Appointments were scheduled
weekly during baseline and treatment phases and all
seizure-relevant data were recorded at the beginning and
end of each phase. Blood samples were taken and
examined for complete blood count (CBC) and liver
function tests.
Finally, the response to oil or placebo, and any side
reactions were assessed. All analyses were done using
the SSPS (version 11.5) statistical software package with
nonparametric Wilcoxon and Freidman tests and a P
value of less than 0.05 was considered significant.
it is also necessary to continue or even increase the
respiratory care such as upper airway toilet, suction of
secretions, chest physiotherapy, non-invasive oxygen
therapy and so on (14). All these measures were applied.
Results
16 patients aged between 3 to 13 years old (mean=8.6±3.6
years old), were recruited in this pilot study; there were
56.3% girls (n=9) and 43.8% boys (n=7). The mean age
at seizure onset was 16.7±15.7 months (3 days to 48
months old). In 62.5% (n=10) of them, history of neonatal
seizures was positive; eight patients (50%) received 2
AEDs, six (37.5%) 3 AEDs and two of them took 4
AEDs.
More than one type of seizure was experienced by 56.3%
(n=9) of patients, the intractable one was taken into
account for classification. Complex partial seizures were
seen in 43.7% (n=7), complex myoclonic seizures in
37.5% (n=6), myoclonic absence in 6.2% (n=1), and
12.5% (n=2) had the Lennox-Gaustat syndrome. Electro
encephalo graphs(EEGs) and computed tomograms of
brain were abnormal in 100% and 68.8% respectively;
Results showed 18.7% (n=3) were seizure free, 75%
(n=12) had over 50% decrease in seizure frequency and
no response to oil was seen in 6.2% (n=1) patient.
Comparing daily seizure frequency before and after oil,
was significant, p=0.007, whereas before and after
placebo, it was p=0.2. Neither were any significant
differences observed between the baseline phases and
treatments (oil or placebo) (p=0.00).
One patient manifested nausea and poor appetite. All lab
tests yielded normal results.
Discussion
Epilepsy is a chronic disease that often requires lifelong
treatment. In compliance with legal and ethical
requirements, the efficacy of new antiepileptic drugs are
usually evaluated in short trials as add-on therapy in
refractory epilepsy (11).  In developing countries,
economic factors make it necessary to consider drug
prices; herbal drugs are normally cheaper and are usually
more accepted among the general population. Rosa
damascena products are available in the market. Despite
searches, we were unable to find any related documented
literature on clinical trials about the anticonvulsant effects
of Rosa in humans. Previous experimental studies on the
effects of purified essential oil showed doses of 500 and
750 mg/kg to have antiepileptic effects on PTZ induced
seizure in rats (8-9-10). In this study, we investigated the
effects of Rosa oil on refractory epilepsy in children, and
found improvement in 18.7% and
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reduction in 75% of attacks. These effects are similar to
the those of new AEDs; in a study investigating
zonisamide as adjunctive treatment for refractory partial
seizures, 28.9% had a reduction in frequency (12) and
a report on the efficacy of levetiracetam as add-on
epilepsy therapy, showed mean reduction in seizure
frequency from baseline, per week over the entire
treatment period was 30.6%.(13). Another study,
researching the efficacy of cloxazolam as add-on therapy
in patients with intractable epilepsy, reported 17% became
seizure free and 39% had over 50% reduction in frequency
(14).
Rosa damascene contains several components such
as graniol, citranellol, farnesol, nerol, eugonol, citral,
terpene, and myercene(1). The compound(s) responsible
for the hypnotic or antiepileptic effects of Rosa damascene
have not yet been confirmed; however other plants
containing compounds such as flavenoids, terpenes and
saponins have been found to have hypnotic effects (15).
It can therefore be suggested that these compounds may
be the ones responsible for hypnotic effect of Rosa
damascena.
Flavenoids with anxiolytic and/or antidepressant activity
have also described in regard to many plant species used
in folk medicine to depress the Central nervous system
(CNS). This effect has been attributed to their affinity
for the central benzodiazepine receptor (16). Hence, it
can be suggested that the flavenoid component of Rosa
damascena contributes in hypnotic effect of this plant
through the benzodiazepine receptors.
Geraniol possesses methoxyphenol forms in its structural
pathway. Behavioral studies have shown that a number
of methoxyphenols and alkylphenols have hypnotic and
anticonvulsant properties. It is conceivable that geraniol
may be at least partially responsible for the antiepileptic
effects of Rosa damascene through the GABA-system.
It has also been reported that saponin regulates the effects
of sedatives, hypnotic and anticonvulsants (17), and other
investigations have found that eugenol has anticonvulsant,
analgesic and local anesthetic effects (18-19).These
questions need to be addressed in future studies.
Conclusion
On the basis of our observations, it may be concluded
that the essential oil of Rosa damascena has anticonvulsant
effects and can improve seizures in children who are
resistant to AEDs. Further, more detailed investigations
on patients with refractory seizures to confirm these
effects and the relevant mechanisms are recommended.
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Table 1: Basic clinical data of patients
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